CN118900687A - 用油酰乙醇酰胺的生物可利用配制物治疗肝脏脂肪变性的方法 - Google Patents

用油酰乙醇酰胺的生物可利用配制物治疗肝脏脂肪变性的方法 Download PDF

Info

Publication number
CN118900687A
CN118900687A CN202280091097.4A CN202280091097A CN118900687A CN 118900687 A CN118900687 A CN 118900687A CN 202280091097 A CN202280091097 A CN 202280091097A CN 118900687 A CN118900687 A CN 118900687A
Authority
CN
China
Prior art keywords
oea
liver
composition
mice
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280091097.4A
Other languages
English (en)
Chinese (zh)
Inventor
D·皮奥梅利
林琳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CN118900687A publication Critical patent/CN118900687A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280091097.4A 2021-12-13 2022-12-12 用油酰乙醇酰胺的生物可利用配制物治疗肝脏脂肪变性的方法 Pending CN118900687A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163265314P 2021-12-13 2021-12-13
US63/265,314 2021-12-13
PCT/US2022/081372 WO2023114722A1 (en) 2021-12-13 2022-12-12 Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide

Publications (1)

Publication Number Publication Date
CN118900687A true CN118900687A (zh) 2024-11-05

Family

ID=86773562

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280091097.4A Pending CN118900687A (zh) 2021-12-13 2022-12-12 用油酰乙醇酰胺的生物可利用配制物治疗肝脏脂肪变性的方法

Country Status (8)

Country Link
US (1) US20250041249A1 (enExample)
EP (1) EP4447950A1 (enExample)
JP (1) JP2025500841A (enExample)
KR (1) KR20240134319A (enExample)
CN (1) CN118900687A (enExample)
AU (1) AU2022416432A1 (enExample)
CA (1) CA3242396A1 (enExample)
WO (1) WO2023114722A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4573920A1 (en) * 2023-12-22 2025-06-25 Centre National de la Recherche Scientifique Texturizing complex comprising oleoylethanolamide and at least one fatty substance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579413A (zh) * 2011-01-14 2012-07-18 傅瑾 油酰乙醇胺及其衍生物的新用途
WO2018187849A1 (en) * 2017-04-13 2018-10-18 Pharmako Biotechnologies Pty Limited Cold-water-dispersible chemical delivery system
US10702487B2 (en) * 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity

Also Published As

Publication number Publication date
AU2022416432A1 (en) 2024-07-25
US20250041249A1 (en) 2025-02-06
KR20240134319A (ko) 2024-09-09
CA3242396A1 (en) 2023-06-22
JP2025500841A (ja) 2025-01-15
WO2023114722A1 (en) 2023-06-22
EP4447950A1 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
Murakami et al. Recent advances in drug therapy for Parkinson's disease
Cao et al. Diquat-induced oxidative stress increases intestinal permeability, impairs mitochondrial function, and triggers mitophagy in piglets
RU2743075C2 (ru) Способы применения агонистов fxr
Song et al. Calpain inhibition ameliorates depression-like behaviors by reducing inflammation and promoting synaptic protein expression in the hippocampus
Mantovani et al. Cancer cachexia: medical management
KR20200106169A (ko) 칸나비노이드를 포함하는 변형 방출형 조성물
US20240325410A1 (en) Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging
TW201834645A (zh) 胺基酸組合物及肝疾病之治療方法
Suguro et al. Combinational applicaton of silybin and tangeretin attenuates the progression of non-alcoholic steatohepatitis (NASH) in mice via modulating lipid metabolism
US20240238232A1 (en) Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions
US11752115B2 (en) PPAR-alpha agonist treatment of neuropsychiatric disorders
ES2580508B1 (es) Composiciones para la prevención y/o tratamiento de los trastornos por uso de alcohol.
US20210069103A1 (en) Oral cannabinoid compositions and methods for treating neuropathic pain
Yasutake et al. Long-term oral administration of osteocalcin induces insulin resistance in male mice fed a high-fat, high-sucrose diet
TW202327589A (zh) 肝病之組合療法
Huang et al. Protective effects of Oxyberberine in 5‐fluorouracil‐induced intestinal mucositis in the mice model
Liu et al. Quercetin attenuates atherosclerosis via modulating apelin signaling pathway based on plasma metabolomics
Sastriques-Dunlop et al. Ketosis prevents abdominal aortic aneurysm rupture through C–C chemokine receptor type 2 downregulation and enhanced extracellular matrix balance
US20250041249A1 (en) Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide
Ikeno et al. Eicosapentaenoic acid suppresses cisplatin-induced muscle atrophy by attenuating the up-regulated gene expression of ubiquitin
JP2023541886A (ja) 超長鎖多価不飽和脂肪酸、エロバノイドヒドロキシル化誘導体、及び使用方法
US20240252496A1 (en) Selective hypothalamus permeable hdac6 inhibitors fortreatment of leptin-resistant obesity
Ho et al. Mixed active metabolites of the SNP-6 series of novel compounds mitigate metabolic dysfunction-associated steatohepatitis and fibrosis: promising results from pre-clinical and clinical trials
US20080207745A1 (en) Orally-absorbed formulation for paromomycin
US20210205333A1 (en) Methods and compositions for treating 25-hydroxyvitamin d deficiency

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination